Similarly, in cancer research, the bifunctional inhibition of PD-1/PD-L1 and TGF-β pathways is a novel approach to enhance antitumor effectiveness (Holmgaard et al., 2018; Wu et al., 2022). Here, TGFB1 is linked to cancer.